38541080|t|Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies.
38541080|a|Antioxidants, usually administered orally through the systemic route, are known to counteract the harmful effects of oxidative stress on retinal cells. The formulation of these antioxidants as eye drops might offer a new option in the treatment of oxidative retinopathies. In this review, we will focus on the use of some of the most potent antioxidants in treating retinal neuropathies. Melatonin, known for its neuroprotective qualities, may mitigate oxidative damage in the retina. N-acetyl-cysteine (NAC), a precursor to glutathione, enhances the endogenous antioxidant defense system, potentially reducing retinal oxidative stress. Idebenone, a synthetic analogue of coenzyme Q10, and edaravone, a free radical scavenger, contribute to cellular protection against oxidative injury. Epigallocatechin-3-gallate (EGCG), a polyphenol found in green tea, possesses anti-inflammatory and antioxidant effects that could be beneficial in cases of retinopathy. Formulating these antioxidants as eye drops presents a localized and targeted delivery method, ensuring effective concentrations reach the retina. This approach might minimize systemic side effects and enhance therapeutic efficacy. In this paper, we also introduce a relatively new strategy: the alkylation of two antioxidants, namely, edaravone and EGCG, to improve their insertion into the lipid bilayer of liposomes or even directly into cellular membranes, facilitating their crossing of epithelial barriers and targeting the posterior segment of the eye. The synergistic action of these antioxidants may offer a multifaceted defense against oxidative damage, holding potential for the treatment and management of oxidative retinopathies. Further research and clinical trials will be necessary to validate the safety and efficacy of these formulations, but the prospect of antioxidant-based eye drops represents a promising avenue for future ocular therapies.
38541080	33	42	Oxidative	Disease	MESH:D028361
38541080	43	55	Eye Diseases	Disease	MESH:D005128
38541080	80	93	Retinopathies	Disease	MESH:D058437
38541080	212	221	oxidative	Disease	MESH:D028361
38541080	343	366	oxidative retinopathies	Disease	MESH:D058437
38541080	461	481	retinal neuropathies	Disease	MESH:D012173
38541080	483	492	Melatonin	Chemical	MESH:D008550
38541080	548	557	oxidative	Disease	MESH:D028361
38541080	580	597	N-acetyl-cysteine	Chemical	MESH:D000111
38541080	599	602	NAC	Chemical	MESH:D000111
38541080	620	631	glutathione	Chemical	MESH:D005978
38541080	714	723	oxidative	Disease	MESH:D028361
38541080	732	741	Idebenone	Chemical	MESH:C036619
38541080	767	779	coenzyme Q10	Chemical	MESH:C024989
38541080	785	794	edaravone	Chemical	MESH:D000077553
38541080	798	810	free radical	Chemical	MESH:D005609
38541080	864	873	oxidative	Disease	MESH:D028361
38541080	882	908	Epigallocatechin-3-gallate	Chemical	MESH:C045651
38541080	910	914	EGCG	Chemical	MESH:C045651
38541080	919	929	polyphenol	Chemical	MESH:D059808
38541080	965	977	inflammatory	Disease	MESH:D007249
38541080	1039	1050	retinopathy	Disease	MESH:D058437
38541080	1388	1397	edaravone	Chemical	MESH:D000077553
38541080	1402	1406	EGCG	Chemical	MESH:C045651
38541080	1444	1449	lipid	Chemical	MESH:D008055
38541080	1698	1707	oxidative	Disease	MESH:D028361
38541080	1770	1793	oxidative retinopathies	Disease	MESH:D058437
38541080	Negative_Correlation	MESH:D000077553	MESH:D028361
38541080	Negative_Correlation	MESH:D000077553	MESH:D005609
38541080	Negative_Correlation	MESH:D000111	MESH:D028361
38541080	Negative_Correlation	MESH:D059808	MESH:D007249
38541080	Negative_Correlation	MESH:C024989	MESH:D028361
38541080	Negative_Correlation	MESH:C045651	MESH:D058437
38541080	Negative_Correlation	MESH:D008550	MESH:D028361
38541080	Positive_Correlation	MESH:D000111	MESH:D005978
38541080	Negative_Correlation	MESH:C045651	MESH:D007249
38541080	Negative_Correlation	MESH:C036619	MESH:D028361

